These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 444274)

  • 1. Pharmacokinetics and hypolipidemic activity of clofibrate-nicotinic acid combinations in rats.
    Cayen MN; Robinson WT; Dubuc J; Dvornik D
    Biochem Pharmacol; 1979 Apr; 28(7):1163-7. PubMed ID: 444274
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate].
    Paltauf F; Pristautz H; el Eisch IA
    Acta Med Austriaca; 1977; 4(3):120-4. PubMed ID: 930544
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triton-induced hyperlipidemia in rats as an animal model for screening hypolipidemic drugs.
    Schurr PE; Schultz JR; Parkinson TM
    Lipids; 1972 Jan; 7(1):68-74. PubMed ID: 5013174
    [No Abstract]   [Full Text] [Related]  

  • 4. Animal models for screening hypolipidemic drugs. III. The response of nicotinic acid and clofibrate in fed and fasted old rats.
    Magnusson O; Andersson I; Nordlund L
    Z Versuchstierkd; 1978; 20(1):46-58. PubMed ID: 636683
    [No Abstract]   [Full Text] [Related]  

  • 5. [Preliminary study of the effects of nicotinic-N-oxide acid causing hypolipidemia administered alone or in combination with clofibrate].
    Palamara G; De Luca G; Materazzi M
    Boll Chim Farm; 1977 Oct; 116(10):596-600. PubMed ID: 607948
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effect of ethofibrate [2-(nicotinoyloxy)ethyl-p-chlorophenoxyisobutyrate] on lipid metabolism. I. Effect on blood lipids in normal and hyperlipemic rats].
    Maroto ML; Priego JG; Piña M; Catalán RE
    Arch Farmacol Toxicol; 1978 Apr; 4(1):25-7. PubMed ID: 697396
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of etofibrate, clofibrate and nicotinic acid on lipid metabolism in hyperlipidemic rats.
    Priego JG; Maroto ML; Piña M; Catalán RE
    Gen Pharmacol; 1979; 10(4):315-8. PubMed ID: 488666
    [No Abstract]   [Full Text] [Related]  

  • 8. The mechanism of action of clofibrate and tetranicotinoylfructose (Bradilan) on the kinetics of plasma free fatty acid and triglyceride transport in type IV and type V hypertriglyceridaemia.
    Kissebah AH; Adams PW; Harrigan P; Wynn V
    Eur J Clin Invest; 1974 Jun; 4(3):163-74. PubMed ID: 4838694
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of hypolipidemic drugs on plasma lipoproteins.
    Levy RI
    Annu Rev Pharmacol Toxicol; 1977; 17():499-510. PubMed ID: 326171
    [No Abstract]   [Full Text] [Related]  

  • 10. Clofibrate and niacin in coronary heart disease.
    JAMA; 1975 Jan; 231(4):360-81. PubMed ID: 1088963
    [No Abstract]   [Full Text] [Related]  

  • 11. Isonicotinates, nicotinates and clofibrates of N-methyl-N-(2-hydroxyethyl or 3-hydroxypropyl)--1,3,3-trimethylbicyclo [2.2.1]heptan-2-endo-amine with hypocholesterolemic and hypolipidemic activity.
    Bondavalli F; Bruno O; Schenone P; Vacca C; De Carlo R; Marmo E
    Farmaco Sci; 1987 Apr; 42(4):251-7. PubMed ID: 3595837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of a lipid-reducing clofibrate-inositolnicotinate combination compared to clofibrate. A double-blind study].
    Schäfer B; Kluthe R
    Med Welt; 1975 Apr; 26(14):655-63. PubMed ID: 1099394
    [No Abstract]   [Full Text] [Related]  

  • 13. [Combination or monotherapy of hyperlipoproteinemia typus IIb, IV, V with clofibrate and m-inositolnicotinate or clofibrinic acid (author's transl)].
    Schwartzkopff W; Zschiedrich M
    Med Klin; 1978 Feb; 73(7):231-9. PubMed ID: 203832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Etofibrate on plasma fibrinogen and plasminogen concentrations in patients with different forms of primary hyperlipoproteinemia.
    Spöttl F; Froschauer J
    Atherosclerosis; 1976; 25(2-3):293-301. PubMed ID: 1008913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hyperlipoproteinaemia types IIa, IIb, IV and V with a combination of clofibrate and inositol nicotinate (author's transl)].
    Wilke H; Frahm H
    Dtsch Med Wochenschr; 1976 Mar; 101(11):401-5. PubMed ID: 1253701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of benzodioxane, chroman and dihydrobenzofuran analogs of clofibrate in a Triton hyperlipemic rat model.
    Newman HA; Heilman WP; Witiak DT
    Lipids; 1973 Jul; 8(7):378-84. PubMed ID: 4724016
    [No Abstract]   [Full Text] [Related]  

  • 17. Binding to plasma lipoproteins of chlorophenoxyisobutyric, tibric and nicotinic acids and their esters.
    Beaumont JL; Dachet C
    Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):41-3. PubMed ID: 1019153
    [No Abstract]   [Full Text] [Related]  

  • 18. Results of treatment of hyperlipidemias: long-term compliance and effect of lipid metabolism.
    Frantz ID
    Adv Exp Med Biol; 1977; 82():649-55. PubMed ID: 920422
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical pharmacokinetics of hypolipidaemic drugs.
    Gugler R
    Clin Pharmacokinet; 1978; 3(6):425-39. PubMed ID: 363332
    [No Abstract]   [Full Text] [Related]  

  • 20. Editorial: Lipid-lowering drugs after myocardial infarction.
    Lancet; 1975 Mar; 1(7905):501-2. PubMed ID: 46964
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.